| Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers (NCT05380882) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 2022-05-01 |
| Hepatic Impairment Study for Lorlatinib in Cancer Patients (NCT03726333) | Pfizer | 2020-01-14 |
| Plasmodium Immunotherapy for Advanced Cancers (NCT03375983) | CAS Lamvac Biotech Co., Ltd. | 2017-11-23 |
| Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient (NCT02801045) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2016-10-20 |
| A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency (NCT02873975) | Dana-Farber Cancer Institute | 2016-10-12 |
| Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors (NCT02478320) | M.D. Anderson Cancer Center | 2016-08-05 |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (NCT02668770) | M.D. Anderson Cancer Center | 2016-05-11 |
| Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis (NCT02623959) | M.D. Anderson Cancer Center | 2016-04-27 |
| Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea (NCT02597478) | M.D. Anderson Cancer Center | 2016-01-04 |
| Occupational Therapy in Palliative Care (NCT02521194) | M.D. Anderson Cancer Center | 2015-11-13 |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies (NCT02571036) | Deciphera Pharmaceuticals, LLC | 2015-11-01 |
| A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors (NCT02561234) | Immedica Pharma AB | 2015-10-22 |
| Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain (NCT02459964) | M.D. Anderson Cancer Center | 2015-09-14 |
| Perception of Palliative Care Encounter (NCT02558257) | M.D. Anderson Cancer Center | 2015-08-16 |
| Edmonton Symptom Assessment Scale: Self-Completion vs. Assisted-Completion (NCT02523378) | M.D. Anderson Cancer Center | 2015-08-13 |
| Registry Study for Personalized Cancer Therapy (NCT02508662) | M.D. Anderson Cancer Center | 2015-07-21 |
| Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion (NCT02498899) | M.D. Anderson Cancer Center | 2015-07-01 |
| Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention (NCT02422329) | M.D. Anderson Cancer Center | 2015-04-30 |
| Cordotomy for Refractory Cancer Pain (NCT02345629) | M.D. Anderson Cancer Center | 2015-03-10 |
| Rational Therapeutics Based on Matched Tumor and Normal Tissue (NCT02272595) | M.D. Anderson Cancer Center | 2014-11-04 |
| A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy (NCT02193672) | M.D. Anderson Cancer Center | 2014-08-01 |
| Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis (NCT01952847) | M.D. Anderson Cancer Center | 2014-07-10 |
| Personalized Oncogenomics (POG) Program of British Columbia (NCT02155621) | British Columbia Cancer Agency | 2014-07-01 |
| MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies (NCT02042989) | M.D. Anderson Cancer Center | 2014-06-27 |
| Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea (NCT01856114) | M.D. Anderson Cancer Center | 2014-05-27 |
| Regorafenib and Cetuximab in Patients With Advanced Malignancy (NCT02095054) | M.D. Anderson Cancer Center | 2014-03-19 |
| Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer (NCT01949662) | M.D. Anderson Cancer Center | 2014-01-01 |
| BiPAP-Vapotherm RCT (NCT01518140) | M.D. Anderson Cancer Center | 2013-12-01 |
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma (NCT01983969) | M.D. Anderson Cancer Center | 2013-11-07 |
| Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea (NCT01832402) | M.D. Anderson Cancer Center | 2013-06-11 |
| CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL) (NCT01653717) | M.D. Anderson Cancer Center | 2013-06-11 |
| Dasatinib and Crizotinib in Advanced Cancer (NCT01744652) | M.D. Anderson Cancer Center | 2013-03-01 |
| Ipilimumab and Lenalidomide in Advanced Cancer (NCT01750983) | M.D. Anderson Cancer Center | 2013-03-01 |
| Dexamethasone Dyspnea Study (NCT01670097) | M.D. Anderson Cancer Center | 2013-01-01 |
| Study of Curcumin, Vorinostat, and Sorafenib (NCT01608139) | M.D. Anderson Cancer Center | 2012-11-01 |
| Genomic Profiling Assay in Phase I (NCT02437617) | M.D. Anderson Cancer Center | 2012-07-13 |
| Study of Vemurafenib, Carboplatin, and Paclitaxel (NCT01636622) | M.D. Anderson Cancer Center | 2012-07-09 |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer (NCT01548144) | M.D. Anderson Cancer Center | 2012-04-01 |
| Breakthrough Dyspnea Fentanyl Study in Cancer Patients (NCT01515566) | M.D. Anderson Cancer Center | 2012-04-01 |
| Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide (NCT01200004) | M.D. Anderson Cancer Center | 2012-04-01 |
| Temsirolimus in Combination With Metformin in Patients With Advanced Cancers (NCT01529593) | M.D. Anderson Cancer Center | 2012-03-26 |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies (NCT01532011) | M.D. Anderson Cancer Center | 2012-03-01 |
| Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers (NCT01563302) | Ionis Pharmaceuticals, Inc. | 2012-02-27 |
| The Effects of Ginseng on Cancer-Related Fatigue (NCT01375114) | M.D. Anderson Cancer Center | 2011-10-14 |
| Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients (NCT01430572) | M.D. Anderson Cancer Center | 2011-10-07 |
| Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) (NCT01201694) | M.D. Anderson Cancer Center | 2011-10-01 |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors (NCT01454804) | M.D. Anderson Cancer Center | 2011-10-01 |
| End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer (NCT01389830) | M.D. Anderson Cancer Center | 2011-06-30 |
| The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer (NCT01193530) | M.D. Anderson Cancer Center | 2011-06-01 |
| Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor (NCT01277744) | M.D. Anderson Cancer Center | 2011-05-09 |
| Tolvaptan in Hyponatremic Cancer Patients (NCT01199198) | M.D. Anderson Cancer Center | 2011-05-01 |
| Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer (NCT01259284) | M.D. Anderson Cancer Center | 2011-01-01 |
| Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab (NCT01213238) | M.D. Anderson Cancer Center | 2010-09-30 |
| Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients (NCT02160366) | M.D. Anderson Cancer Center | 2010-09-27 |
| Trientine and Carboplatin in Advanced Malignancies (NCT01178112) | M.D. Anderson Cancer Center | 2010-07-01 |
| A First in Man Study of MABp1 in Patients With Advanced Cancers (NCT01021072) | Janssen Research & Development, LLC | 2010-03-31 |
| Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients (NCT01003626) | M.D. Anderson Cancer Center | 2010-03-01 |
| TTP607 in Refractory Solid Malignancies (NCT00939172) | M.D. Anderson Cancer Center | 2010-03-01 |
| Lapatinib With Sirolimus or Metformin (NCT01087983) | M.D. Anderson Cancer Center | 2010-03-01 |
| Physician Perceptions About Parenteral Hydration in Latin America and Spain (NCT01011140) | M.D. Anderson Cancer Center | 2010-01-01 |
| HAI Abraxane With Gemcitabine and Bevacizumab (NCT01057264) | M.D. Anderson Cancer Center | 2010-01-01 |
| Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study (NCT01024166) | M.D. Anderson Cancer Center | 2009-11-01 |
| High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer (NCT00934128) | M.D. Anderson Cancer Center | 2009-08-01 |
| Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing (NCT00909207) | M.D. Anderson Cancer Center | 2009-07-01 |
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients (NCT00877773) | M.D. Anderson Cancer Center | 2009-04-01 |
| An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status (NCT00903734) | M.D. Anderson Cancer Center | 2009-04-01 |
| Erlotinib in Combination With Cetuximab (NCT00895362) | M.D. Anderson Cancer Center | 2009-04-01 |
| Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) (NCT00836927) | Merck Sharp & Dohme LLC | 2009-02-01 |
| Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol (NCT00851032) | M.D. Anderson Cancer Center | 2009-02-01 |
| Hepatic Arterial Infusion (HAI) of Abraxane (NCT00732836) | M.D. Anderson Cancer Center | 2008-06-01 |
| Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers (NCT00473720) | Yale University | 2007-05-01 |
| The Effects of Thalidomide on Symptom Clusters (NCT00379353) | M.D. Anderson Cancer Center | 2006-09-01 |
| LY2275796 in Advanced Cancer (NCT00903708) | M.D. Anderson Cancer Center | 2006-09-01 |
| The Survey About Resting Metabolic Rate and Its Related Factors in Terminal Patients (NCT00208013) | China Medical University Hospital | 2005-07-01 |
| Azacytidine and Valproic Acid in Patients With Advanced Cancers (NCT00496444) | M.D. Anderson Cancer Center | 2005-05-01 |
| Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging (NCT00499382) | M.D. Anderson Cancer Center | 2004-09-01 |